Roche : New Data For Evrysdi Reinforce Long-Term Efficacy And Safety Profile In Types 2 And 3 SMA
20/3 07:25
(RTTNews) - Roche (RHHBY) said that new four year data for its Evrysdi reinforced long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy....